Significant antifracture efficacy of oral ibandronate in women with low bone mass

被引：0
|
作者：
Lorenc, R
Felsenberg, D
Stakkestad, JA
Gibride, J
Schimmer, RC
机构：
[1] Childrens Mem Inst, Warsaw, Poland
[2] Univ Klinikum Benjamin Franklin, Osteoporose Forsch Grp, Berlin, Germany
[3] CECOR AS, Haugesund, Norway
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：452 / 452
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
    Uehara, Masashi
    Nakamura, Yukio
    Suzuki, Takako
    Nakano, Masaki
    Takahashi, Jun
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (22)
  • [32] EFFICACY OF ORAL IBANDRONATE VERSUS 3 MG INTRAVENOUS IBANDRONATE
    Paun, D. L.
    Andrei, C.
    Petris, R.
    Ene, N.
    Dumitrache, C.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 153 - 153
  • [33] COMPARISON OF THE EFFECTIVENESS OF MONTHLY INTRAVENOUS IBANDRONATE AND MONTHLY ORAL IBANDRONATE IN HEMODIALYSIS PATIENTS WITH LOW BONE MINERAL DENSITY
    Fujii, Takayuki
    Koshizaka, Junya
    Yamauchi, Nobuaki
    Saito, Kaiji
    Morimoto, Mayu
    Terasaki, Noriko
    Tanaka, Hiroaki
    Suzuki, Satoshi
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 560 - 560
  • [34] The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer
    Utkan, G
    Büyükçelik, A
    Yalçyn, B
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (10) : 1574 - 1574
  • [35] Oral ibandronate can normalize bone mass density in the region of osteoblastic and osteoclastic metastasis
    Vartanyan, K. F.
    [J]. BONE, 2007, 40 (06) : S185 - S185
  • [36] Significant increases in bone mineral density observed from 1 to 2 years in women with PMO after treatment with monthly oral ibandronate.
    Miller, P. D.
    Simonelli, C.
    Leweicki, E. M.
    Barr, C. E.
    Genant, H. K.
    Zaidi, M.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S289 - S289
  • [37] EFFICACY OF ONCE-MONTHLY ORAL BISPHOSPHONATES (IBANDRONATE AND RISEDRONATE) IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
    Epstein, S.
    McCloskey, E.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 146 - 146
  • [38] Antifracture efficacy of risedronate: Prediction by change in bone resorption markers
    Eastell, R
    Barton, I
    Hannon, RA
    Garnero, P
    Chines, A
    Pack, S
    Delmas, PD
    [J]. OSTEOPOROSIS INTERNATIONAL, 2002, 13
  • [39] Daily oral ibandronate prevents bone loss in postmenopausal women without osteoporosis.
    McClung, M
    Wasnich, RD
    Recker, R
    Cauley, JA
    Ensrud, K
    Burdeska, A
    Mahoney, P
    Hughes, C
    Chesnut, C
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S157 - S157
  • [40] Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis
    McClung, MR
    Wasnich, RD
    Recker, R
    Cauley, JA
    Chesnut, CH
    Ensrud, KE
    Burdeska, A
    Mills, T
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (01) : 11 - 18
12345